Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. [electronic resource]
Producer: 20190924Description: 3819-3825 p. digitalISSN:- 1558-8238
- Adult
- Aged
- Animals
- Child
- Female
- Hematologic Neoplasms -- drug therapy
- Humans
- Infant
- Male
- Membrane Glycoproteins -- antagonists & inhibitors
- Mice
- Middle Aged
- Oncogene Fusion
- Oncogene Proteins, Fusion -- antagonists & inhibitors
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins c-ets -- antagonists & inhibitors
- Pyrazoles -- therapeutic use
- Pyrimidines -- therapeutic use
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Receptor, trkA -- genetics
- Receptor, trkB -- antagonists & inhibitors
- Receptor, trkC -- genetics
- Repressor Proteins -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
- Young Adult
- ETS Translocation Variant 6 Protein
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.